Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for measuring concentrations of biomolecules

a biomolecule and concentration technology, applied in the direction of instruments, assay labels, material analysis, etc., can solve the problems of increasing public health problems, loss of memory, cognitive function, independence and death, and disease that takes a heavy personal and financial toll on the patient, the family, and society

Inactive Publication Date: 2014-03-06
C2N DIAGNOSTICS
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Alzheimer's Disease (AD) is the most common cause of dementia and is an increasing public health problem.
AD leads to loss of memory, cognitive function, and ultimately independence and death.
The disease takes a heavy personal and financial toll on the patient, the family, and society.
Currently, there are some medications that modify symptoms, however, there are no disease-modifying treatments.
However, by the time clinical diagnosis of AD is made, extensive neuronal loss has already occurred (Price et al.
Currently, there are no means of identifying the pathophysiologic changes that occur in AD before the onset of clinical symptoms or of effectively measuring the effects of treatments that may prevent the onset or slow the progression of the disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for measuring concentrations of biomolecules
  • Methods for measuring concentrations of biomolecules
  • Methods for measuring concentrations of biomolecules

Examples

Experimental program
Comparison scheme
Effect test

example 1

Stable Isotope Kinetic Labeling

[0080]This example illustrates the improvements developed over the SILK methodology. A cell culture media was generated with a known ratio of labeled to unlabeled Aβ. This standard curve media was thereafter used to test the detection and quantitation of the 29-x peptides of Aβ. Using this media, a series of tests were performed to improve the solubility of the 29-x peptides as well as to establish improved chromatography conditions in order to increase detection of the peptides.

[0081]Increased Solubility of the 29-x Peptides—

[0082]The original SILK-Aβ™ methodology was modified by use of 0.025% of detergent, for example Tween-20, Triton, or CHAPS, instead of using 0.5M guanidine for the IP and washing steps. The peptides are kept in the 0.025% detergent solution during digestion as well and until injected into the mass spectrometer. Aβ is a very hydrophobic peptide and the addition of Tween-20 greatly improves the solubility and mass spectrometer signa...

example 2

Quantitation Standard

[0088]This example demonstrates that spiking of quantitation standard can be used for calculation of the ratio between endogenous peptides and spiked peptides. Thus, spiking in known amounts of labeled Aβ 37, Aβ 38, Aβ 39, Aβ 40 and Aβ 42 allows specific quantitation of those isoforms in addition to quantitation of the total Aβ concentration in the sample.

[0089]Due to the lead time of manufacturing labeled peptides we originally used unlabeled peptides as the spike in and used media from cells grown in 100% 13C6 leucine as the unknown. We spiked in unlabeled Aβ 38 and Aβ42 into 100% 13C6 leucine media and measured the ratios. As more unlabeled peptide was spiked into the media the tracer to tracee ratio (TTR, in this experiment defined as ratio of unlabeled to labeled) of both the 17-28 peptide and the 29-38 peptide increased linearly. (See FIGS. 3 and 4).

[0090]This illustrates the feasibility of measuring the concentration of these peptides based upon spiking a...

example 3

Quantitation Standard to Calculate Absolute Concentration

[0091]This example demonstrates use of the Quantitation Standard to calculate the production or clearance rates of biomolecules of interest, which is used to calculate absolute concentration of those biomolecules.

[0092]A sample containing Aβ or other peptide isoforms (including, but not limited to Aβ 1-37, Aβ 1-38, Aβ 1-39, Aβ 1-40, Aβ 1-42) in both unlabeled form, as well as labeled with 13C6-leucines (the labeled leucine is incorporated into the sample by the subject's natural biological processes) is spiked with Quantitation Standard. The ratio of labeled to unlabeled peptide over time is used to calculate kinetic production and clearance rates (metabolism) of the peptide in the subject. The ratios of labeled or unlabeled peptide to Quantitation Standard are used to calculate concentrations of the respective versions of the peptide.

[0093]The biomolecule (e.g., protein or peptide) is immunoprecipitated utilizing an antibody ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods for measuring the absolute concentration of a biomolecule of interest in a subject. Such biomolecules may be implicated in one or more neurological and neurodegenerative diseases or disorders. Also provided is a method for determining whether a therapeutic agent affects the in vivo metabolism of a central nervous system derived biomolecule. Also provided are kits for performing the methods of the invention.

Description

CROSS REFERENCE TO RELATED APPLICATION(S)[0001]This application is a divisional of U.S. Ser. No. 13 / 132,307, filed on Sep. 23, 2011, which is a 35 U.S.C. §371 National Stage application of PCT Application No. PCT / US09 / 66810, filed Dec. 4, 2009, which claims the benefit under 35 U.S.C. §119(e) to U.S. Ser. No. 61 / 120,326, filed Dec. 5, 2008, and U.S. Ser. No. 61 / 120,329, filed Dec. 5, 2008. The disclosure of each of the prior applications is considered part of, and is incorporated by reference in, the disclosure of this application.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The invention generally relates to methods for the diagnosis and treatment of neurological and neurodegenerative diseases, disorders, and associated processes.[0004]2. Background Information[0005]Alzheimer's Disease (AD) is the most common cause of dementia and is an increasing public health problem. It is currently estimated to afflict 5 million people in the United States, with an expected i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/68
CPCG01N33/6896G01N33/537G01N33/58G01N2496/00G01N2458/15G01N2800/2821G01N33/6848G01N2800/28
Inventor WEST, TIMPAOLETTI, ANDREW COREY
Owner C2N DIAGNOSTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com